Attenuation of rejected cells transformed with adenovirus E3
US6491909B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2000 |
| Grant date | Dec 10, 2002 |
| Priority date | — |
| Expiry date | Aug 1, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16643
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method and vectors to express a gene or genes, derived from a virus, which block allograft rejection. One class of genes blocks the intracellular transport and/or intracellular maturation within the cells of proteins called MHC class I products. Without limitation as to theory, it is believed that blocking the appearance of this class of proteins on the transplanted cell's surface, prevents the host's immune system from rejecting the graft. Another class of proteins acts to permit TNF &agr;-mediated cell cytolysis. In one embodiment, the invention is directed towards engrafting the cells that secrete insulin, which are called alternatively, pancreatic &bgr;-cells and islet cells, and thereby provide a treatment of diabetes mellitus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.